转移
癌症研究
血小板
血小板活化
下调和上调
过剩1
葡萄糖转运蛋白
医学
癌症
生物
巨核细胞
化学
内分泌学
内科学
细胞生物学
造血
干细胞
生物化学
胰岛素
基因
作者
Biying Wu,Ying Ye,Sisi Xie,Yintao Li,Xiaoting Sun,Mingqi Lv,Ling Yang,Nan Cui,Qiying Chen,Lasse D. Jensen,Dongmei Cui,Guichun Huang,Jiane Zuo,Shaochong Zhang,Wen Li,Yunlong Yang
出处
期刊:Cancer Research
[American Association for Cancer Research]
日期:2021-09-17
卷期号:81 (21): 5506-5522
被引量:12
标识
DOI:10.1158/0008-5472.can-21-1180
摘要
High blood glucose has long been established as a risk factor for tumor metastasis, yet the molecular mechanisms underlying this association have not been elucidated. Here we describe that hyperglycemia promotes tumor metastasis via increased platelet activity. Administration of glucose, but not fructose, reprogrammed the metabolism of megakaryocytes to indirectly prime platelets into a prometastatic phenotype with increased adherence to tumor cells. In megakaryocytes, a glucose metabolism-related gene array identified the mitochondrial molecular chaperone glucose-regulated protein 75 (GRP75) as a trigger for platelet activation and aggregation by stimulating the Ca2+-PKCα pathway. Genetic depletion of Glut1 in megakaryocytes blocked MYC-induced GRP75 expression. Pharmacologic blockade of platelet GRP75 compromised tumor-induced platelet activation and reduced metastasis. Moreover, in a pilot clinical study, drinking a 5% glucose solution elevated platelet GRP75 expression and activated platelets in healthy volunteers. Platelets from these volunteers promoted tumor metastasis in a platelet-adoptive transfer mouse model. Together, under hyperglycemic conditions, MYC-induced upregulation of GRP75 in megakaryocytes increases platelet activation via the Ca2+-PKCα pathway to promote cancer metastasis, providing a potential new therapeutic target for preventing metastasis. SIGNIFICANCE: This study provides mechanistic insights into a glucose-megakaryocyte-platelet axis that promotes metastasis and proposes an antimetastatic therapeutic approach by targeting the mitochondrial protein GRP75.
科研通智能强力驱动
Strongly Powered by AbleSci AI